Source: Arch Internal Med
Area: News
This review outlines the clinical effectiveness and potential harms of off-label intravitreal administration of anti-VEGF drugs (pegaptanib, bevacizumab, ranibizumab, and aflibercept) for diabetic macular oedema.
Uncategorized